Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenza Conteduca

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Blood|June 14, 2008
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitisDomenico Sansonno, Felicia Anna Tucci, Laura Troiani, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 16, 2017
Urinary RNA-based biomarkers for prostate cancer detectionFilippo Martignano, Lorena Rossi, Antonio Maugeri, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2013
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinibAlfredo Tartarone, Chiara Lazzari, Rosa Lerose, et al.
Critical Reviews in Oncology/Hematology|July 11, 2020
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinomaCristian Lolli, Amelia Altavilla, Vincenza Conteduca, et al.
Therapeutic Advances in Medical Oncology|June 18, 2024
Androgen receptor, PARP signaling, and tumor microenvironment: the 'perfect triad' in prostate cancer?Marianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, et al.
Frontiers in Oncology|October 19, 2020
Plasma <i>AR</i> Copy Number Changes and Outcome to Abiraterone and EnzalutamideGiorgia Gurioli, Vincenza Conteduca, Cristian Lolli, et al.
Critical Reviews in Oncology/Hematology|December 14, 2020
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectivesNicole Brighi, Vincenza Conteduca, Cristian Lolli, et al.
European Urology Oncology|December 3, 2024
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic DiseaseMarianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, et al.
Virchows Archiv : an International Journal of Pathology|October 4, 2023
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP)Alessia Cimadamore, Pasquale Rescigno, Vincenza Conteduca, et al.
The Prostate|September 30, 2014
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamideVincenza Conteduca, Salvatore Luca Burgio, Cecilia Menna, et al.
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Blood|June 14, 2008
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitisDomenico Sansonno, Felicia Anna Tucci, Laura Troiani, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 16, 2017
Urinary RNA-based biomarkers for prostate cancer detectionFilippo Martignano, Lorena Rossi, Antonio Maugeri, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2013
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinibAlfredo Tartarone, Chiara Lazzari, Rosa Lerose, et al.
Critical Reviews in Oncology/Hematology|July 11, 2020
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinomaCristian Lolli, Amelia Altavilla, Vincenza Conteduca, et al.
Therapeutic Advances in Medical Oncology|June 18, 2024
Androgen receptor, PARP signaling, and tumor microenvironment: the 'perfect triad' in prostate cancer?Marianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, et al.
Frontiers in Oncology|October 19, 2020
Plasma <i>AR</i> Copy Number Changes and Outcome to Abiraterone and EnzalutamideGiorgia Gurioli, Vincenza Conteduca, Cristian Lolli, et al.
Critical Reviews in Oncology/Hematology|December 14, 2020
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectivesNicole Brighi, Vincenza Conteduca, Cristian Lolli, et al.
European Urology Oncology|December 3, 2024
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic DiseaseMarianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, et al.
Virchows Archiv : an International Journal of Pathology|October 4, 2023
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP)Alessia Cimadamore, Pasquale Rescigno, Vincenza Conteduca, et al.
The Prostate|September 30, 2014
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamideVincenza Conteduca, Salvatore Luca Burgio, Cecilia Menna, et al.
Pageof 16